Comments on the use of ozone therapy in post-acute sequelae of COVID-19 (PASC) patients

Int Immunopharmacol. 2024 Oct 25:140:112770. doi: 10.1016/j.intimp.2024.112770. Epub 2024 Aug 3.

Authors

Salvatore Chirumbolo¹, Luigi Valdenassi², Marianno Franzini², Tommaso Richelmi², Umberto Tirelli³

Affiliations

¹ Department of Engineering for Innovation Medicine, University of Verona, Verona, Italy. Electronic address: [email protected].
² Italian Scientific Society of Oxygen Ozone Therapy (SIOOT), Bergamo and High Master School of Oxygen Ozone Therapy, University of Pavia, Italy.
³ Tirelli Medical Group Pordenone and Former Head Director of the Oncology Unit National Cancer Research Aviano, PN, Italy.

PMID: 39098230
DOI: 10.1016/j.intimp.2024.112770

No abstract available

Publication types

Letter

MeSH terms

COVID-19* / complications
Humans
Ozone* / therapeutic use
Post-Acute COVID-19 Syndrome
SARS-CoV-2*

Substances

Ozone